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Human immunodeﬁciency virus (HIV) positive patients may develop vasculitis, either medi-
ated by immunological factors or by direct vascular injury. We  describe a patient who
developed manifestations suggestive of extremities vasculitis with no identiﬁable risk fac-
tors  other than HIV, Epstein Barr and Herpes Simplex Virus (HSV) type 1 co-infection.
Physicians should be aware that vasculitis may have a heterogeneous presentation and
occur associated with HIV infection. Although unusual, this association should be recog-asculitis
IV
pstein Barr virus
erpes Simplex Virus
nized  for early proper treatment and prevention of ischemia.
© 2015 Elsevier Editora Ltda. All rights reserved.
antibodies were negative. ECG, chest X-ray, Doppler echocar-ase  report
 30-year-old black female was referred from a primary center
ith a history of a 2-week intermittent claudication with
aresthesias and hypothermia in extremities, most intense in
he lower limbs. She was a non-smoker HIV-infected patient
n irregular highly active antiretroviral therapy (HAART)
ith efavirenz, emitricitabine and tenofovir. She denied
ever, diabetes mellitus and prior peripheral vascular disease.
xamination revealed dehydration, temperature 36.7 ◦C,
espiratory rate 20/min, pulse rate 50/min, and immeasurable
P in all four limbs. Brachial, radial and femoral pulses were
ymmetrical with decreased amplitude. Popliteal, tibial and
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413-8670/© 2015 Elsevier Editora Ltda. All rights reserved.dorsalis pulses were not palpable bilaterally. The extremities
were pale, cold and cyanotic with capillary ﬁlling time of
6 s. Remaining exam without changes. Initial investigations
revealed CD4T lymphocytes 460 cells/mL, normal sedimen-
tation rate, C reactive protein, and lipid proﬁle; absence of
leukocytosis and thrombocytopenia. Positive Epstein Barr and
HSV type 1 IgG antibodies. Venereal disease research labo-
ratory, serology for hepatitis B and C, cytomegalovirus, HSV
type 2, antinuclear antibodies, anticytoplasmic antibodies,
anticardiolipin antibodies, and antineutrophil cytoplasmicdiogram, and abdominal-pelvic ultrasound were normal.
CT angiography revealed normal aorta, iliac, femoral, and
popliteal arteries with no atherosclerotic plaques; bilateral
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Figs. 1 and 2 – CT angiography of the lower extremities showing almost total absence of vascular opaciﬁcation, bilateral and
 no symmetrical, distally to popliteal trifurcations (arrows), with
and symmetrical absence of vascular lumen opaciﬁcation
distally to popliteal trifurcations; absence of thrombi, areas
of stenosis or atherosclerotic calciﬁcation. The evidence of
impaired peripheral perfusion, in the absence of atheroscle-
rotic/thrombotic lesions and drug use (besides those included
on HAART) led us to assume the diagnosis of vasculitis of
medium and small vessels of the extremities in the context of
HIV, Epstein Barr, and HSV type 1 co-infection. The patient was
treated with HAART, steroids, vasodilators, and anti-platelet
aggregation agents. Eight months after discharge and on regu-
lar HAART, the viral load was undetectable, CD4T lymphocytes
536 cells/L, and the patient was asymptomatic (Figs. 1 and 2).
Discussion
This report describes the occurrence of a suspected vasculitis
of the extremities in a patient with HIV infection and pos-
itive IgG antibodies for Epstein–Barr virus and HSV type 1.
The remarkable feature in the patient’s presentation was the
occurrence of the described events in the context HIV infec-
tion without severe immunosuppression (CD4 <200 cells/mL).
Vasculitis is characterized by injury of the blood vessels that
induces vascular lumens reduction and tissular ischemia.
There is great heterogeneity in clinical presentation and its
1pathogenesis is not fully understood. In the reported patient
the signs of poor peripheral perfusion discordant with the
neurological status and cardiac function suggested the diag-
nosis of vasculitis. HIV-related vasculitis has been describedvisible areas of stenosis or atheromatous calciﬁcation.
by several authors, has an occurrence estimated at 1% and
is therefore considered rare.2–6 It may be caused by direct
vascular injury or be mediated by immunological factors.2–5
It especially occurs in severe immunosuppressed cases, with
CD4T lymphocytes below 200 cells/mL, in the context of oppor-
tunistic infections or in the absence of identiﬁable agents.2,3,7
According to the literature, when the immune system is com-
promised, even ubiquitous agents such as Epstein Barr Virus
and HSV can cause vasculitis.5,6 Some predisposing factors,
which may be an independent cause of vasculitis are tuber-
culosis, parasitic and autoimmune diseases; however, the
patient had neither manifestations of these diseases nor labo-
ratory evidence. Another confounding factor was the patient’s
normal inﬂammatory markers, which delayed the diagno-
sis of vasculitis until admission to the ward. Interestingly,
a study by Borg and Dasgupta reported normal inﬂammatory
markers in 30% of patients with vasculitis later revealed by
imaging techniques.8 Some imaging ﬁndings may suggest the
diagnosis: on ultrasound, hypoechoic areas along the arte-
rial wall also described as pearl necklace; on angiography,
increased vascular wall thickness and reduced vascular lumen
opacity.8,9 The gold-standard for the diagnosis of vasculitis
is the histopathological study. Unfortunately, we  were not
able to perform it because the patient did not consent. It
would contribute to a better understanding of the subclini-
cal vascular abnormalities and their etiology. We should also
point out that this is a limitation of our report. Treatment
is HAART, plasma exchanges, and corticosteroids. Vascu-
lopathy in the context of HIV-infected patients on HAART
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ay be caused by drug-related toxicity. Although HAART
as changed the pattern of HIV infection and the course
f AIDS, it may cause adverse reactions such as endothe-
ial dysfunction, vasculitis, and coagulation disorders leading
o thromboembolism, systemic arterial hypertension, coro-
ary artery disease, and peripheral vascular disease. There is
vidence that some HAART regimens, such as those includ-
ng zidovudine, efavirenz and protease inhibitors, interrupt
ndothelial cell junctions and cytoskeleton action of the
ndothelial cells leading to endothelial dysfunction.8 Drug
nduced hypersensitivity vasculitis typically involves small
essels and its pathologic mechanisms include T-cell recog-
ition of proteins or deposition of immune complexes in
lood-vessel walls. Hypersensitivity reactions should be con-
idered as a possible etiology of vasculitis in HIV-infected
atients on HAART. It is plausible to consider that in this
eport, vasculitis could have been associated with drug related
oxicity given that the patient referred multiple interruptions
f an efavirenz, emitricitabine and tenofovir based HAART.
owever, against this hypothesis, the patient remained on the
ame previously used HAART regimen with no interruptions
nd the vasculitis regressed. According to Lo and Plutzky,9 HIV
rug treatment interruptions have also been associated with
ncreased cardiovascular event rates. Data from the Strate-
ies for Management of Anti-Retroviral Therapy (SMART) trial
uggest that activation of inﬂammatory and coagulation path-
ays induced by HIV infection may be further worsened by
reatment interruption and thus further increase the risk of
eath among HIV infected patients.9 According to Guillevin,
IV-related vasculitis do not appear to recur.10 In conclusion,
hysicians should be aware that vasculitis may have a het-
rogeneous presentation and can occur in association to HIV
nfection. Although unusual, this association should be recog-
ized for proper early treatment and prevention of extremity
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